Tandem Diabetes Care, Inc. (TNDM)

Compare

16.88

-0.78

(-4.42%)

At close: April 4 at 4:00:02 PM EDT

16.80

-0.08

(-0.47%)

After hours: April 4 at 6:06:27 PM EDT

Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

SAN DIEGO, April 03, 2025--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results.

Business Wire yesterday

TNDM
-4.42%
Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound?

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 7 days ago

TNDM
-4.42%
FRE.DE
3 Reasons to Sell TNDM and 1 Stock to Buy Instead

Shareholders of Tandem Diabetes would probably like to forget the past six months even happened. The stock dropped 54.1% and now trades at $20.22. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.

StockStory 9 days ago

TNDM
-4.42%
Tandem announces publication of results from trial of Control-IQ+ AID technology

Tandem Diabetes (TNDM) Care announced publication by The New England Journal of Medicine of results from the company’s pivotal trial of Control-IQ+ automated insulin delivery technology in people with type 2 diabetes. Additional study findings were presented today during a symposium at the 18th International Conference on Advanced Technologies & Treatments for Diabetes in Amsterdam, the Netherlands. Results published in NEJM demonstrate significant improvements in time in range and hemoglobin A1

TipRanks 15 days ago

TNDM
-4.42%
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

MedTech Dive 15 days ago

PODD
-4.49%
TNDM
-4.42%
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes

SAN DIEGO, March 19, 2025--Tandem Diabetes Care, Inc. announced NEJM publication of positive results from Control-IQ+ AID technology pivotal trial in type 2 diabetes.

Business Wire 16 days ago

TNDM
-4.42%
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology

Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.

Zacks 16 days ago

TNDM
-4.42%
BSX

CAH
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States

SAN DIEGO, March 18, 2025--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company’s advanced hybrid closed-loop algorithm. Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes. Pumps pre-loaded with t

Business Wire 17 days ago

TNDM
-4.42%
3 Healthcare Stocks Walking a Fine Line

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 9.4%. This performance was disheartening since the S&P 500 held its ground.

StockStory 17 days ago

BTSG

TNDM
-4.42%
Reasons to Hold TNDM Stock in Your Portfolio for Now

A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.

Zacks 24 days ago

TNDM
-4.42%
BSX

CAH
Bernstein downgrades Tandem Diabetes on market share loss concerns

Investing.com -- Bernstein downgraded Tandem Diabetes Care (NASDAQ:TNDM) to Market-Perform from Outperform, citing market share losses and rising competition in the insulin pump space. The firm also lowered its price target to $25 from $35.

Investing.com last month

TNDM
-4.42%
Loss-Making Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Expected To Breakeven In The Medium-Term

With the business potentially at an important milestone, we thought we'd take a closer look at Tandem Diabetes Care...

Simply Wall St. last month

TNDM
-4.42%
Tandem Diabetes Crashes 35% As Light Outlook Rattles Pump-Maker's Shares

Tandem Diabetes shares crashed Thursday after the insulin pump-maker issued light sales guidance for 2025.

Investor's Business Daily last month

TNDM
-4.42%
TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss

Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.

Zacks last month

TNDM
-4.42%
CAH

RMD
Q4 2024 Tandem Diabetes Care Inc Earnings Call

Q4 2024 Tandem Diabetes Care Inc Earnings Call

Thomson Reuters StreetEvents last month

TNDM
-4.42%
Tandem Diabetes Care (TNDM) Slid in Q4 Despite Strong Results

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S. stocks saw gains in the fourth quarter, primarily fueled by a clear result in the U.S. presidential election. Against this backdrop, Class A shares of the […]

Insider Monkey last month

TNDM
-4.42%
Tandem Diabetes Care Inc (TNDM) Q4 2024 Earnings Call Highlights: Record Sales Growth and ...

Tandem Diabetes Care Inc (TNDM) reports robust sales growth and outlines strategic plans for 2025, despite facing market challenges and operational hurdles.

GuruFocus.com last month

TNDM
-4.42%
Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks last month

TNDM
-4.42%
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of -76% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

TNDM
-4.42%
Tandem Diabetes’s (NASDAQ:TNDM) Q4 Sales Beat Estimates But Stock Drops 12.2%

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 35% year on year to $282.6 million. The company expects next quarter’s revenue to be around $221.5 million, coming in 1.3% above analysts’ estimates. Its GAAP profit of $0.01 per share was significantly above analysts’ consensus estimates.

StockStory last month

TNDM
-4.42%

Performance Overview

Return	TNDM	S&P 500 (^GSPC)
YTD	-53.14%	-13.73%
1-Year	-49.11%	-1.42%
3-Year	-85.86%	+10.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tandem Diabetes Care, Inc. (TNDM)

Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound?

3 Reasons to Sell TNDM and 1 Stock to Buy Instead

Tandem announces publication of results from trial of Control-IQ+ AID technology

Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data

Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes

TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology

Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States

3 Healthcare Stocks Walking a Fine Line

Reasons to Hold TNDM Stock in Your Portfolio for Now

Bernstein downgrades Tandem Diabetes on market share loss concerns

Loss-Making Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Expected To Breakeven In The Medium-Term

Tandem Diabetes Crashes 35% As Light Outlook Rattles Pump-Maker's Shares

TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss

Q4 2024 Tandem Diabetes Care Inc Earnings Call

Tandem Diabetes Care (TNDM) Slid in Q4 Despite Strong Results

Tandem Diabetes Care Inc (TNDM) Q4 2024 Earnings Call Highlights: Record Sales Growth and ...

Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates

Tandem Diabetes’s (NASDAQ:TNDM) Q4 Sales Beat Estimates But Stock Drops 12.2%

Performance Overview